Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Health Psychol Res ; 10(5): 56782, 2022.
Article in English | MEDLINE | ID: mdl-36726475

ABSTRACT

Purpose of Review: Seizures are a hyperexcitable, and hypersynchronous imbalance between excitatory and inhibitory factors (E/I imbalance) in neurotransmission, and epilepsy is the recurrent manifestation of seizures within a reasonable time frame and without being attributable to a reversible cause. Brivaracetam is a derivative of the antiepileptic agent, levetiracetam, that is used as adjuvant therapy for focal onset seizures. It was approved by the FDA in 2016 and has shown promising results with minimal adverse effect reactions in clinical trials. Recent Findings: Brivaracetam has been used in multiple clinical trials at various dosages in adults that have partial-onset seizures refractory to conventional treatment. A meta-analysis in 2016 showed that brivaracetam as adjunctive therapy was statically significant in its reduction of adults with drug-refractory seizure frequency.1 The most commonly reported adverse effects that patients who were taking brivaracetam experienced were somnolence, headache, and dizziness. Further studies are necessary to conclude long term efficacy and safety profile of brivaracetam. Conclusion: The treatment of epilepsy with pharmacologic agents is a difficult task due to balancing the efficacy of the drug with the side effect profile that will allow for the best quality of life for the patient. There are approximately 30 antiepileptic agents for clinicians to choose from. Brivaracetam is a novel antiepileptic agent that was approved for use by the FDA in 2016 and is showing promising results as monotherapy and adjunctive therapy in individuals with drug-refractory focal seizures while minimizing adverse drug reactions.

2.
Psychopharmacol Bull ; 51(3): 125-149, 2021 06 01.
Article in English | MEDLINE | ID: mdl-34421149

ABSTRACT

Post-traumatic stress disorder (PTSD) has become one of the most common psychiatric diagnosis in the United States specifically within the veteran population. The current treatment options for this debilitating diagnosis include trauma-focused psychotherapies along with selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI).1 MDMA has recently been shown as a novel therapeutic agent with promisingly results in the treatment of PTSD. MDMA is a psychoactive compound traditionally categorized as a psychedelic amphetamine that deemed a Schedule I controlled substance in the 1980s. Prior to its status as a controlled substance, it was used by psychotherapists for an array of psychiatric issues. In more recent times, MDMA has resurfaced as a potential therapy for PTSD and the data produced from randomized, controlled trials back the desire for MDMA to be utilized as an effective pharmacologic therapy in conjunction with psychotherapy.2.


Subject(s)
Hallucinogens , N-Methyl-3,4-methylenedioxyamphetamine , Stress Disorders, Post-Traumatic , Veterans , Adult , Hallucinogens/pharmacology , Hallucinogens/therapeutic use , Humans , N-Methyl-3,4-methylenedioxyamphetamine/pharmacology , N-Methyl-3,4-methylenedioxyamphetamine/therapeutic use , Psychotherapy , Stress Disorders, Post-Traumatic/drug therapy
3.
Neurol Int ; 13(2): 252-265, 2021 Jun 09.
Article in English | MEDLINE | ID: mdl-34207493

ABSTRACT

Medical management of epilepsy seeks to eliminate or to reduce the frequency of seizures, help patients maintain a normal lifestyle, and maintain psychosocial and occupational activities, while avoiding the negative side effects of long-term treatment. Current FDA approved drugs have been shown to have similar efficacy; however, they all share a commonality of having side effects that have the potential to significantly reduce a patient's quality of life. Cenobamate, a newly-FDA approved drug used to treat partial-onset seizures in adult patients, has demonstrated promise in that it works on two proposed mechanisms that are commonly associated with epilepsy. Cenobamate acts as a positive allosteric modulator of the GABAA ion channels and is effective in reducing repetitive neuronal firing by inhibition of voltage-gated sodium channels, although the complete mechanism of action is currently unknown. The efficacy of Cenobamate with its low toxicity and adverse drug reaction profile emphasizes the need to further evaluate antiepileptic therapies containing sulfamoylphenyl and/or carbamate moieties in their chemical structure. Recent studies have found more patients to be seizure free during the maintenance period when compared to placebo. The most common side effects reported in with Cenobamate are somnolence, dizziness, headache, nausea, and fatigue. There are currently ongoing phase III studies looking to further evaluate the long-term benefits of Cenobamate and investigate adverse events.

4.
Best Pract Res Clin Anaesthesiol ; 33(4): 465-486, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31791564

ABSTRACT

Chronic pain management techniques have evolved in recent years. With regard to this, ultrasound (US) technology has become a standard for most acute pain procedures and essential for postsurgical pain relief and enhanced recovery after surgery protocols. This manuscript summarizes clinical studies evaluating US use for chronic pain management and compares efficacy with standard techniques including fluoroscopy (FL). US possesses several unique benefits when compared with FL, including elimination of radiation exposure while providing similar clinical outcomes. In summary, US use for chronic pain procedures is emerging as a viable, safe, and effective modality. Additional studies are needed to best appreciate US and its role in chronic pain management.


Subject(s)
Chronic Pain/diagnostic imaging , Chronic Pain/therapy , Nerve Block/methods , Pain Management/methods , Ultrasonography, Interventional/methods , Anesthetics, Local/administration & dosage , Humans , Nerve Block/instrumentation , Pain Management/instrumentation , Pain Measurement/instrumentation , Pain Measurement/methods , Ultrasonography, Interventional/instrumentation
5.
Anesthesiol Clin ; 36(4): 615-626, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30390782

ABSTRACT

Drug abuse and addiction are persistent problems in the United States and around the world. This is an ongoing issue for health care providers, as substance abuse is seen in 25% to 40% of patients admitted to hospitals for general treatment. Many patients with substance use disorders have a higher risk for adverse events; however, only a small percentage will volunteer information regarding prior substance use. This article discusses the present opioid crisis, mechanisms behind chronic pain and substance abuse, current clinical findings, treatment therapies, and abuse deterrents.


Subject(s)
Analgesics, Opioid/therapeutic use , Chronic Pain/drug therapy , Chronic Pain/therapy , Pain Management/methods , Substance-Related Disorders/complications , Humans , Substance-Related Disorders/prevention & control
6.
Best Pract Res Clin Anaesthesiol ; 32(2): 125-136, 2018 Jun.
Article in English | MEDLINE | ID: mdl-30322454

ABSTRACT

There has been significant research to develop an ideal synthetic opioid. Opioids with variable properties possessing efficacy and with reduced side effects have been synthesized when compared to previously used agents. An opioid modulator is a drug that can produce both agonistic and antagonistic effects by binding to different opioid receptors and therefore cannot be classified as one or the other alone. These compounds can differ in their structures while still possessing opioid-mediated actions. This review will discuss TRV130 receptor modulators and other novel opioid receptor modulators, including Mitragyna "Kratom," Ignavine, Salvinorin-A, DPI-289, UFP-505, LP1, SKF-10,047, Cebranopadol, Naltrexone-14-O-sulfate, and Naloxegol. In summary, the structural elucidation of opioid receptors, allosteric modulation of opioid receptors, new opioid modulators and agonists, the employment of optogenetics, optopharmacology, and next-generation sequencing of opioid receptor genes and related functionality should create exciting new avenues for research and therapeutic development to treat conditions including pain, opioid abuse, and addiction.


Subject(s)
Analgesics, Opioid/metabolism , Analgesics, Opioid/pharmacology , Receptors, Opioid/agonists , Receptors, Opioid/metabolism , Animals , Diterpenes, Clerodane/metabolism , Diterpenes, Clerodane/pharmacology , Humans , Indoles/metabolism , Indoles/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/metabolism , Naltrexone/pharmacology , Spiro Compounds/metabolism , Spiro Compounds/pharmacology , Thiophenes/metabolism , Thiophenes/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...